CASP8 Knockout A-375 Cell Line

The choice depends on whether you are studying CASP8 in BRAF V600E melanoma context for combination therapy research. The Knockout line is the standard tool for asking whether CASP8 is required for these processes — CASP8 has been characterized in melanoma immune evasion (CASP8 silencing is common in melanoma); CASP8 status influences death receptor-induced apoptosis and necroptosis. Overexpression is useful for studying CASP8 gain-of-function effects. For BRAF-driven melanoma research, the EDITGENE CASP8 Knockout in A-375 is highly relevant — A-375 is BRAF V600E-mutant and the principal in vitro melanoma model. This product complements the parallel CASP8 Knockouts in L-02 (normal hepatocyte) and A-549 (lung cancer) for cross-background validation. Rescue with wild-type or catalytically-dead CASP8 enables structure-function studies. The knockout is valuable for studying BRAF/MEK inhibitor (vemurafenib, dabrafenib, trametinib, cobimetinib) combination therapy effects on melanoma apoptosis, immune checkpoint inhibitor (pembrolizumab, ipilimumab) mechanism in melanoma, and CASP8-mediated immunogenic cell death.

Primary applications: • Melanoma apoptosis: death receptor-induced apoptosis in BRAF V600E melanoma context. • BRAF/MEK inhibitor combination: vemurafenib, dabrafenib, trametinib effects on apoptosis in CASP8-null melanoma. • Immunotherapy mechanism: in heterologous immune-tumor co-culture systems, CASP8's role in pembrolizumab/ipilimumab-induced melanoma cell death. • Cross-background validation: parallel analysis with CASP8 KOs in L-02 and A-549 (both available) for systematic cross-tissue context studies. EDITGENE recommends this BRAF V600E melanoma model for researchers investigating CASP8 in BRAF-driven cancer apoptosis and immunotherapy mechanism studies.

Yes. CASP8 rescue experiments in A-375 are well-suited for BRAF melanoma research: • Construct design: same considerations as CASP8/L-02 rescue. • Catalytically-dead C360S rescue: enables separation of proteolytic from scaffolding functions in BRAF V600E melanoma context. • BRAF/MEK inhibitor combination studies: rescue with WT CASP8 enables systematic assessment of CASP8 contribution to vemurafenib/dabrafenib/trametinib-induced melanoma apoptosis. • Functional readout: rescue should restore death receptor- and BRAF/MEK inhibitor-induced apoptosis. A-375-specific considerations: • A-375 is a human melanoma cell line with BRAF V600E mutation — the principal in vitro model for BRAF-driven melanoma biology and BRAF/MEK inhibitor research (vemurafenib, dabrafenib, encorafenib for BRAF; trametinib, cobimetinib, binimetinib for MEK). • Lentiviral transduction is supported with moderate efficiency. • MAPK pathway-driven cancer biology is the dominant feature of A-375.